Department of Surgery, Osaka University, Graduate School of Medicine.Nippon rinsho. Japanese journal of clinical medicine 11/2008; 66(10):2004-7.
The existence of anti-tumor immune system has been reported and was proved by many experiments. A lot of tumor specific antigens as a target of immune system were identified and some have been applied for cancer vaccine. Since NY-ESO-1, one of cancer-testis antigens, was reported to be expressed frequently in cancers and to possess strong immunogenicity, it is also used for worldwide cancer vaccine trials. We have performed a cancer vaccine clinical trial with NY-ESO-1 protein and observed NY-ESO -1 specific immune responses in most of patients vaccinated. Some patients showed preferable clinical responses. Cancer vaccine was developed rapidly in the last decade, however there still left several problems to be resolved for the spread of cancer vaccine.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.